
NATURE . COM {
}
Title:
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials | British Journal of Cancer
Description:
British Journal of Cancer - Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
Website Age:
30 years and 10 months (reg. 1994-08-11).
Matching Content Categories {π}
- Education
- Health & Fitness
- Science
Content Management System {π}
What CMS is nature.com built with?
Custom-built
No common CMS systems were detected on Nature.com, and no known web development framework was identified.
Traffic Estimate {π}
What is the average monthly size of nature.com audience?
π Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Nature.com Make Money? {πΈ}
Display Ads {π―}
The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.
Ads are managed by yourbow.com. Particular relationships are as follows:
Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.comReseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.comHow Much Does Nature.com Make? {π°}
Display Ads {π―}
$63,100 per month
Estimations show Nature.com's display ad online revenue falls between $42,042 and $115,616 per month.
Keywords {π}
cancer, google, scholar, article, activity, drug, nature, vivo, models, hollow, fibre, tumor, cas, preclinical, development, vitro, compounds, content, tested, human, cell, anticancer, cookies, journal, open, clinical, trials, xenograft, screening, practice, oncology, privacy, data, access, national, agents, correlation, assay, intraperitoneal, response, research, devita, hellmann, rosenberg, principles, lippincottraven, philadelphia, analysis, british, nci,
Topics {βοΈ}
nature portfolio medicinal chemistry libraries nature privacy policy advertising social media 0/ reprints anticancer drug development pharmaceutical policy permissions personal data xenograft data preclinical drug development hollow fiber assay animal models utilized phase ii trials data protection cancer drug discovery cancer chemotherapeutic agents vitro antitumor screen privacy developmental therapeutics program hollow fibre responses molecular docking studies hollow fibre assay hollow fibre activity journals search log explore content early clinical trials tumor panel screening subcutaneous activity combined tumor development national cancer institute' human cancer histology national cancer institute anti-cancer effect european economic area 4h-chromen-7-yl ]quinoline-based heterocycles knowledge-based approach americal chemical society ox40 agonist alexander accepting optional cookies microculture tetrazolium assay anti-proliferative activity finding xenograft activity vivo tumour models hydrogen-bonding factors pre-clinical models antitumor drugs
Schema {πΊοΈ}
WebPage:
mainEntity:
headline:Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
description:An analysis of the activity of compounds tested in pre-clinical in vivo and in vitro assays by the National Cancer Institute's Developmental Therapeutics Program was performed. For 39 agents with both xenograft data and Phase II clinical trials results available, in vivo activity in a particular histology in a tumour model did not closely correlate with activity in the same human cancer histology, casting doubt on the correspondence of the pre-clinical models to clinical results. However, for compounds with in vivo activity in at least one-third of tested xenograft models, there was correlation with ultimate activity in at least some Phase II trials. Thus, an efficient means of predicting activity in vivo models remains desirable for compounds with anti-proliferative activity in vitro. For 564 compounds tested in the hollow fibre assay which were also tested against in vivo tumour models, the likelihood of finding xenograft activity in at least one-third of the in vivo models tested rose with increasing intraperitoneal hollow fibre activity, from 8% for all compounds tested to 20% in agents with evidence of response in more than 6 intraperitoneal fibres (P< 0.0001). Intraperitoneal hollow fibre activity was also found to be a better predictor of xenograft activity than either subcutaneous hollow fibre activity or intraperitoneal plus subcutaneous activity combined. Since hollow fibre activity was a useful indicator of potential in vivo response, correlates with hollow fibre activity were examined for 2304 compounds tested in both the NCI 60 cell line in vitro cancer drug screen and hollow fibre assay. A positive correlation was found for histologic selectivity between in vitro and hollow fibre responses. The most striking correlation was between potency in the 60 cell line screen and hollow fibre activity; 56% of compounds with mean 50% growth inhibition below 10Γ’ΒΒ7.5 M were active in more than 6 intraperitoneal fibres whereas only 4% of compounds with a potency of 10Γ’ΒΒ4 M achieved the same level of hollow fibre activity (P< 0.0001). Structural parameters of the drugs analysed included compound molecular weight and hydrogen-bonding factors, both of which were found to be predictive of hollow fibre activity. ΓΒ© 2001 Cancer Research Campaign
datePublished:2001-05-15T00:00:00Z
dateModified:2011-11-16T00:00:00Z
pageStart:1424
pageEnd:1431
sameAs:https://doi.org/10.1054/bjoc.2001.1796
keywords:
anticancer drug discovery
in vitro-to-in vivo correlations
clinical trials
Biomedicine
general
Cancer Research
Epidemiology
Molecular Medicine
Oncology
Drug Resistance
image:
isPartOf:
name:British Journal of Cancer
issn:
1532-1827
0007-0920
volumeNumber:84
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:J I Johnson
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
type:Person
name:S Decker
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
type:Person
name:D Zaharevitz
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
type:Person
name:L V Rubinstein
affiliation:
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
type:Organization
type:Person
name:J M Venditti
affiliation:
name:SAIC-Frederick
address:
name:SAIC-Frederick, Frederick
type:PostalAddress
type:Organization
type:Person
name:S Schepartz
affiliation:
name:SAIC-Frederick
address:
name:SAIC-Frederick, Frederick
type:PostalAddress
type:Organization
type:Person
name:S Kalyandrug
affiliation:
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
type:Organization
type:Person
name:M Christian
affiliation:
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
type:Organization
type:Person
name:S Arbuck
affiliation:
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
type:Organization
type:Person
name:M Hollingshead
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
type:Person
name:E A Sausville
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
description:An analysis of the activity of compounds tested in pre-clinical in vivo and in vitro assays by the National Cancer Institute's Developmental Therapeutics Program was performed. For 39 agents with both xenograft data and Phase II clinical trials results available, in vivo activity in a particular histology in a tumour model did not closely correlate with activity in the same human cancer histology, casting doubt on the correspondence of the pre-clinical models to clinical results. However, for compounds with in vivo activity in at least one-third of tested xenograft models, there was correlation with ultimate activity in at least some Phase II trials. Thus, an efficient means of predicting activity in vivo models remains desirable for compounds with anti-proliferative activity in vitro. For 564 compounds tested in the hollow fibre assay which were also tested against in vivo tumour models, the likelihood of finding xenograft activity in at least one-third of the in vivo models tested rose with increasing intraperitoneal hollow fibre activity, from 8% for all compounds tested to 20% in agents with evidence of response in more than 6 intraperitoneal fibres (P< 0.0001). Intraperitoneal hollow fibre activity was also found to be a better predictor of xenograft activity than either subcutaneous hollow fibre activity or intraperitoneal plus subcutaneous activity combined. Since hollow fibre activity was a useful indicator of potential in vivo response, correlates with hollow fibre activity were examined for 2304 compounds tested in both the NCI 60 cell line in vitro cancer drug screen and hollow fibre assay. A positive correlation was found for histologic selectivity between in vitro and hollow fibre responses. The most striking correlation was between potency in the 60 cell line screen and hollow fibre activity; 56% of compounds with mean 50% growth inhibition below 10Γ’ΒΒ7.5 M were active in more than 6 intraperitoneal fibres whereas only 4% of compounds with a potency of 10Γ’ΒΒ4 M achieved the same level of hollow fibre activity (P< 0.0001). Structural parameters of the drugs analysed included compound molecular weight and hydrogen-bonding factors, both of which were found to be predictive of hollow fibre activity. ΓΒ© 2001 Cancer Research Campaign
datePublished:2001-05-15T00:00:00Z
dateModified:2011-11-16T00:00:00Z
pageStart:1424
pageEnd:1431
sameAs:https://doi.org/10.1054/bjoc.2001.1796
keywords:
anticancer drug discovery
in vitro-to-in vivo correlations
clinical trials
Biomedicine
general
Cancer Research
Epidemiology
Molecular Medicine
Oncology
Drug Resistance
image:
isPartOf:
name:British Journal of Cancer
issn:
1532-1827
0007-0920
volumeNumber:84
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:J I Johnson
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
type:Person
name:S Decker
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
type:Person
name:D Zaharevitz
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
type:Person
name:L V Rubinstein
affiliation:
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
type:Organization
type:Person
name:J M Venditti
affiliation:
name:SAIC-Frederick
address:
name:SAIC-Frederick, Frederick
type:PostalAddress
type:Organization
type:Person
name:S Schepartz
affiliation:
name:SAIC-Frederick
address:
name:SAIC-Frederick, Frederick
type:PostalAddress
type:Organization
type:Person
name:S Kalyandrug
affiliation:
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
type:Organization
type:Person
name:M Christian
affiliation:
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
type:Organization
type:Person
name:S Arbuck
affiliation:
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
type:Organization
type:Person
name:M Hollingshead
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
type:Person
name:E A Sausville
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
["Periodical","PublicationVolume"]:
name:British Journal of Cancer
issn:
1532-1827
0007-0920
volumeNumber:84
Organization:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
name:SAIC-Frederick
address:
name:SAIC-Frederick, Frederick
type:PostalAddress
name:SAIC-Frederick
address:
name:SAIC-Frederick, Frederick
type:PostalAddress
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:J I Johnson
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
name:S Decker
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
name:D Zaharevitz
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
name:L V Rubinstein
affiliation:
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
type:Organization
name:J M Venditti
affiliation:
name:SAIC-Frederick
address:
name:SAIC-Frederick, Frederick
type:PostalAddress
type:Organization
name:S Schepartz
affiliation:
name:SAIC-Frederick
address:
name:SAIC-Frederick, Frederick
type:PostalAddress
type:Organization
name:S Kalyandrug
affiliation:
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
type:Organization
name:M Christian
affiliation:
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
type:Organization
name:S Arbuck
affiliation:
name:Cancer Therapy Evaluation Program, National Cancer Institute
address:
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
type:PostalAddress
type:Organization
name:M Hollingshead
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
name:E A Sausville
affiliation:
name:Developmental Therapeutics Program
address:
name:Developmental Therapeutics Program, Bethesda
type:PostalAddress
type:Organization
PostalAddress:
name:Developmental Therapeutics Program, Bethesda
name:Developmental Therapeutics Program, Bethesda
name:Developmental Therapeutics Program, Bethesda
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
name:SAIC-Frederick, Frederick
name:SAIC-Frederick, Frederick
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
name:Developmental Therapeutics Program, Bethesda
name:Developmental Therapeutics Program, Bethesda
External Links {π}(68)
- Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3335022
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Feasibility%20of%20drug%20screening%20with%20panels%20of%20human%20tumor%20cell%20lines%20using%20a%20microculture%20tetrazolium%20assay&journal=Cancer%20Res&volume=48&pages=589-601&publication_year=1988&author=Alley%2CMC&author=Scudiero%2CDA&author=Monks%2CA&author=Hursey%2CML&author=Czerwinski%2CMJ&author=Fine%2CDL&author=Abbott%2CBJ&author=Mayo%2CJG&author=Shoemaker%2CRH&author=Boyd%2CMR?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Cancer%20Principles%20and%20Practice%20of%20Oncology&publication_year=1982&author=DeVita%2CVT&author=Hellmann%2CS&author=Rosenberg%2CSA?
- Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Cancer%20Principles%20and%20Practice%20of%20Oncology&publication_year=1985&author=DeVita%2CVT&author=Hellmann%2CS&author=Rosenberg%2CSA
- What's the profit of http://scholar.google.com/scholar_lookup?&title=Cancer%20Principles%20and%20Practice%20of%20Oncology&publication_year=1989&author=DeVita%2CVT&author=Hellmann%2CS&author=Rosenberg%2CSA?
- How much profit does http://scholar.google.com/scholar_lookup?&title=Cancer%20Principles%20and%20Practice%20of%20Oncology&publication_year=1993&author=DeVita%2CVT&author=Hellmann%2CS&author=Rosenberg%2CSA make?
- What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Cancer%20Principles%20and%20Practice%20of%20Oncology&publication_year=1997&author=DeVita%2CVT&author=Hellmann%2CS&author=Rosenberg%2CSA?
- http://scholar.google.com/scholar_lookup?&title=Development%20of%20human%20tumor%20xenograft%20models%20for%20in%20vivo%20evaluation%20of%20new%20antitumor%20drugs&journal=Contrib%20Oncol&volume=42&pages=1-22&publication_year=1992&author=Dykes%2CDJ&author=Abbott%2CBJ&author=Mayo%2CJG&author=Harrison%2CSD&author=Laster%2CWR&author=Simpson-Herren%2CL&author=Griswold%2CDP's total income per month
- How much does https://doi.org/10.1016%2FS0065-230X%2808%2960917-3 gross monthly?
- Revenue of http://scholar.google.com/scholar_lookup?&title=Investigation%20of%20diverse%20systems%20for%20cancer%20chemotherapy%20screening&journal=Cancer%20Res%20Suppl&doi=10.1016%2FS0065-230X%2808%2960917-3&volume=3&pages=1-125&publication_year=1955&author=Gellhorn%2CA&author=Hirschberg%2CE
- Revenue of https://doi.org/10.1021%2Fcc9800071
- How much revenue does http://scholar.google.com/scholar_lookup?&title=A%20knowledge-based%20approach%20in%20designing%20combinatorial%20or%20medicinal%20chemistry%20libraries%20for%20drug%20discovery.%201.%20A%20qualitative%20and%20quantitative%20characterization%20of%20known%20drug%20databases&journal=J%20Comb%20Chem&doi=10.1021%2Fcc9800071&volume=1&pages=55-68&publication_year=1999&author=Ghose%2CAK&author=Viswanadhan%2CVN&author=Wendoloski%2CJJ bring in?
- What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10519381?
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Tumor%20development%20under%20angiogenic%20signaling%3A%20a%20dynamical%20theory%20of%20tumor%20growth%2C%20treatment%20response%2C%20and%20postvasular%20dormancy&journal=Cancer%20Res&volume=59&pages=4770-4775&publication_year=1999&author=Hahnfeldt%2CP&author=Panigrahy%2CD&author=Folkman%2CJ&author=Hlatky%2CL
- Find out how much http://scholar.google.com/scholar_lookup?&title=The%20hollow%20fiber%20assay&pages=109-120&publication_year=1999&author=Hollingshead%2CM&author=Plowman%2CJ&author=Alley%2CM&author=Mayo%2CJ&author=Sausville%2CE earns monthly
- Explore the financials of https://doi.org/10.1016%2FS0169-409X%2896%2900423-1
- Monthly income for http://scholar.google.com/scholar_lookup?&title=Experimental%20and%20computational%20approaches%20to%20estimate%20solubility%20and%20permeability%20in%20drug%20discovery%20and%20development%20settings.%20Adv&journal=Drug%20Delivery%20Rev&doi=10.1016%2FS0169-409X%2896%2900423-1&volume=23&pages=3-25&publication_year=1997&author=Lipinski%2CCA&author=Lombardo%2CF&author=Dominy%2CBW&author=Feeney%2CPJ
- What's https://doi.org/10.1093%2Fjnci%2F83.11.757's gross income?
- Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Feasibility%20of%20a%20high-flux%20anticancer%20drug%20screen%20using%20a%20diverse%20panel%20of%20cultured%20human%20tumor%20cell%20lines&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2F83.11.757&volume=83&pages=757-766&publication_year=1991&author=Monks%2CA&author=Scudiero%2CD&author=Skehan%2CP&author=Shoemaker%2CR&author=Paull%2CK&author=Vistica%2CD&author=Hose%2CC&author=Langley%2CJ&author=Cronise%2CP&author=Vaigro-Wolff%2CA&author=Gray-Goodrich%2CM&author=Campbell%2CH&author=Mayo%2CJ&author=Boyd%2CM
- How much income is https://doi.org/10.1093%2Fjnci%2F81.14.1088 earning monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=Display%20and%20analysis%20of%20patterns%20of%20differential%20activity%20of%20drugs%20against%20human%20tumor%20cell%20lines%3A%20development%20of%20the%20mean%20graph%20and%20COMPARE%20algorithm&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2F81.14.1088&volume=81&pages=1088-1092&publication_year=1989&author=Paull%2CKD&author=Shoemaker%2CRH&author=Hodes%2CL&author=Monks%2CA&author=Scudiero%2CDA&author=Rubinstein%2CL&author=Plowman%2CJ&author=Boyd%2CMR make?
- Profit of http://scholar.google.com/scholar_lookup?&title=Prediction%20of%20biochemical%20mechanism%20of%20action%20from%20the%20in%20vitro%20antitumor%20screen%20of%20the%20National%20Cancer%20Institute&pages=9-45&publication_year=1995&author=Paull%2CKD&author=Hamel%2CE&author=Malspeis%2CL
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9850044 generate monthly?
- How much income does http://scholar.google.com/scholar_lookup?&title=Angiogenesis%20in%20the%20hollow%20fiber%20tumor%20model%20influences%20drug%20delivery%20to%20tumor%20cells%3A%20implications%20for%20anticancer%20drug%20screening%20programs&journal=Cancer%20Res&volume=58&pages=5263-5266&publication_year=1998&author=Phillips%2CRM&author=Pearce%2CJ&author=Loadman%2CPM&author=Bibby%2CMC&author=Cooper%2CPA&author=Swaine%2CDJ&author=Double%2CJA have?
- How much does https://link.springer.com/doi/10.1007/978-1-4615-8152-9_6 bring in each month?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Human%20tumor%20xenograft%20models&doi=10.1007%2F978-1-4615-8152-9_6&pages=101-125&publication_year=1997&author=Plowman%2CJ&author=Dykes%2CDJ&author=Hollingshead%2CM&author=Simpson-Herren%2CL&author=Alley%2CMC produce monthly?
- Check the income stats for https://doi.org/10.1023%2FA%3A1008333901925
- What's the income generated by http://scholar.google.com/scholar_lookup?&title=Evolving%20approaches%20to%20cancer%20drug%20discovery%20and%20development%20at%20the%20National%20Cancer%20Institute%2C%20USA&journal=Annals%20Oncol&doi=10.1023%2FA%3A1008333901925&volume=10&pages=1287-1291&publication_year=1999&author=Sausville%2CEA&author=Feigal%2CE each month?
- What's the total monthly financial gain of https://doi.org/10.1016%2F0277-5379%2890%2990196-Z?
- What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Correlation%20of%20drug%20response%20in%20patients%20and%20in%20the%20clonogenic%20assay%20with%20solid%20human%20tumour%20xenografts&journal=Eur%20J%20Cancer&doi=10.1016%2F0277-5379%2890%2990196-Z&volume=26&pages=901-905&publication_year=1990&author=Scholz%2CCC&author=Berger%2CDP&author=Winterhalter%2CBR&author=Henss%2CH&author=Fiebig%2CHH?
- Profit of http://scholar.google.com/scholar_lookup?&title=Preclinical%20drug%20development%3A%20rationale%20and%20methods&journal=Seminars%20Oncol&volume=8&pages=349-361&publication_year=1981&author=Venditti%2CJM
- How much money does https://doi.org/10.1016%2FS1054-3589%2808%2960263-X generate?
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=Current%20NCI%20preclinical%20antitumor%20screening%20in%20vivo%3A%20results%20of%20tumor%20panel%20screening%2C%201976%E2%80%931982%2C%20and%20future%20directions&journal=Adv%20Pharmacol%20Chemother&doi=10.1016%2FS1054-3589%2808%2960263-X&volume=20&pages=1-19&publication_year=1984&author=Venditti%2CJM&author=Wesley%2CRA&author=Plowman%2CJ
- See how much http://scholar.google.com/scholar_lookup?&title=The%20chemotherapy%20program%20of%20the%20National%20Cancer%20Institute%3A%20history%2C%20analysis%20and%20plans&journal=Cancer%20Chemother%20Rep&volume=50&pages=349-540&publication_year=1966&author=Zubrod%2CCG&author=Schepartz%2CS&author=Leiter%2CJ&author=Endicott%2CKM&author=Carrese%2CLM&author=Baker%2CCG makes per month
- How much does https://citation-needed.springer.com/v2/references/10.1054/bjoc.2001.1796?format=refman&flavour=references pull in?
- What's the income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J%20I%20Johnson?
- Earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J%20I%20Johnson%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- Income figures for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=S%20Decker
- Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22S%20Decker%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=D%20Zaharevitz generate?
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22D%20Zaharevitz%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's financial summary
- How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=L%20V%20Rubinstein generate?
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22L%20V%20Rubinstein%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- Earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J%20M%20Venditti
- What's the financial outcome of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J%20M%20Venditti%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=S%20Schepartz income
- Explore the financials of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22S%20Schepartz%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=S%20Kalyandrug
- What's the income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22S%20Kalyandrug%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M%20Christian make?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M%20Christian%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en net monthly?
- What is the monthly revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=S%20Arbuck?
- What's the income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22S%20Arbuck%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M%20Hollingshead's revenue stream
- See how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M%20Hollingshead%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en makes per month
- What's the monthly money flow for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=E%20A%20Sausville?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22E%20A%20Sausville%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earn?
- Get to know https://s100.copyright.com/AppDispatchServlet?title=Relationships%20between%20drug%20activity%20in%20NCI%20preclinical%20in%20vitro%20and%20in%20vivo%20models%20and%20early%20clinical%20trials&author=J%20I%20Johnson%20et%20al&contentID=10.1054%2Fbjoc.2001.1796©right=The%20Author%28s%29&publication=0007-0920&publicationDate=2001-05-15&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY-NC-SA's earnings
- How much profit is https://citation-needed.springer.com/v2/references/10.1054/bjoc.2001.1796?format=refman&flavour=citation making per month?
- How profitable is https://doi.org/10.1186/s42826-024-00195-6?
- What are the earnings of https://doi.org/10.1186/s12885-022-10428-3?
- How much does https://doi.org/10.1038/s41416-023-02186-1 gross monthly?
- What's the profit of https://doi.org/10.1007/s00262-023-03433-3?
- How much does https://doi.org/10.1186/s40545-022-00445-9 pull in?
- Financial intake of https://www.protocols.io/
- What are the total earnings of https://www.natureindex.com/?
- Find out how much http://www.naturechina.com earns monthly
- What's the monthly income of https://www.natureasia.com/ja-jp?
Analytics and Tracking {π}
- Google Tag Manager
Libraries {π}
- Prism.js
- Zoom.js
Emails and Hosting {βοΈ}
Mail Servers:
- mxa-002c5801.gslb.pphosted.com
- mxb-002c5801.gslb.pphosted.com
Name Servers:
- pdns1.ultradns.net
- pdns2.ultradns.net
- pdns3.ultradns.org
- pdns4.ultradns.org
- pdns5.ultradns.info
- pdns6.ultradns.co.uk